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Introduction
Methotrexate (MTX) is the agent of first choice for the
treatment of children with Juvenile Idiopathic Arthritis
(JIA). Leflunomide (LFN) has demonstrated to be an
effective alternative to MTX. There is a lack of evidence
regarding the advantages of combined treatment of
MTX plus LFN in JIA.
Objectives
To evaluate the safety and effectiveness of the combined
therapy with Methotrexate (MTX) and Leflunomide
(LFN) in patients with Juvenile Idiopathic Arthritis (JIA)
in clinical practice.
Methods
We conducted a retrospective descriptive study of
patients with JIA visited in a single Unit of Pediatric
Rheumatology who had been treated with the combina-
tion of MTX plus LFN. All patients were classified
according to the International League of Associations
for Rheumatology (ILAR) criteria. Included data were:
demographics, JIA subtype, reason for starting combined
treatment, time on treatment, withdrawals, causes of
discontinuation, efficacy and safety (both assessed at
baseline and every 6 months during 2 years of treat-
ment). Safety was evaluated analyzing adverse events
(AE) based on clinical and physical findings and labora-
tory values. Ocular effectiveness was assessed grading
uveitis according to the Standardization of Uveitis
Nomenclature Working Group (SUN) recommenda-
tions. Articular effectiveness was assessed by means of:
pediatric core set variables with exception of C-HAQ,
Protein-C-reactive, JADAS scores 10, 27 and 71, and
applying the criteria of minimal disease activity, 30%
improvement, inactivity and remission.
Results
Nineteen patients (16 female, 3 male) were included:
12 oligoarthritis (63%), 4 polyarthritis (21%), 2 psoria-
tic arthritis (11%) and 1 undifferentiated arthritis (5%).
The mean age at diagnosis was 57 months (4.75 years
± 3.65) and at initiation of combined treatment was
112 months (9.37 years ± 4.12).The mean duration of
MTX+LFN treatment was 28.6 months ± 31.6 (range
5-144). An improvement was observed in each variable
studied. JADAS scores had improved a 60% at last fol-
low up compared to the baseline. The best rates of
improvement were observed at 18 months of treat-
ment: 91.7% improved at least 30%, 83.3% met criteria
for minimal disease activity, 83.3% for inactivity and
66.7% for clinical remission. Eight children had uveitis
and all of them were in clinical remission according to
the SUN criteria at last follow up. Overall, 28 AE were
reported. There were no serious AE. The most fre-
quently reported AE was upper respiratory tract infec-
tion. One of the two DMARD was stopped in 11
patients (58%) due to AE in 4 children, inefficacy or
loss of efficacy in 3 and clinical remission in 4. Gastro-
intestinal intolerance was the more common cause of
discontinuation of one of the two DMARD. Among
patients who withdrew the combined treatment 4
switched to anti-TNF therapy and 7 continued mono-
therapy with MTX or LFN. Eight children are still on
MTX plus LFN.
Conclusion
In our patients with JIA the combined therapy of MTX
plus LFN was well-tolerated and proved to be effective.
Most of the patients experienced a substantial improve-
ment either articular or ocular. AE were generally mild.
LFN plus MTX could be a safe and effective alternative
for patients with JIA who do not respond to MTX or
LFN in monotherapy.
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